These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8960265)

  • 21. [Cefuroxime axetil (Zinnat)--laboratory and clinical study].
    Vyhnánek F; Hejzlar M; Procházka M; Pellar T; St'astná L; Silarová J; Kittnar E; Vedral T
    Rozhl Chir; 1990 Oct; 69(10):668-73. PubMed ID: 2263996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli.
    Cornaglia G; Ligozzi M; Bauernfeind A; Satta G; Fontana R
    New Microbiol; 1994 Jul; 17(3):203-10. PubMed ID: 7968655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New special agents registered in Austria. Zinnat (cefuroxime axetil, glaxo)].
    Gartler W
    Wien Klin Wochenschr; 1991; 103(10):306-12. PubMed ID: 1858381
    [No Abstract]   [Full Text] [Related]  

  • 24. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability.
    Stoeckel K; Hofheinz W; Laneury JP; Duchene P; Shedlofsky S; Blouin RA
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2602-6. PubMed ID: 9756762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Stepwise therapy of community-acquired pneumonia. Results of cefuroxime and cefuroxime axetil study].
    Iakovlev SV; Suvorova MP; Dvoretskiĭ LI; Vlasenko NA; Shakhova TV
    Antibiot Khimioter; 1998; 43(6):7-11. PubMed ID: 9644527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dose and food on the bioavailability of cefuroxime axetil.
    Finn A; Straughn A; Meyer M; Chubb J
    Biopharm Drug Dispos; 1987; 8(6):519-26. PubMed ID: 3427209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].
    Kees F; Naber KG
    Infection; 1990; 18 Suppl 3():S150-4. PubMed ID: 2079377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefuroxime axetil.
    Emmerson AM
    J Antimicrob Chemother; 1988 Aug; 22(2):101-4. PubMed ID: 3053551
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.
    Garton AM; Rennie RP; Gilpin J; Marrelli M; Shafran SD
    J Antimicrob Chemother; 1997 Dec; 40(6):903-6. PubMed ID: 9462447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel C-3 cyclic ether cephalosporins and their orally absorbed prodrug esters.
    Bateson JH; Burton G; Fell SC; Smulders HC
    J Antibiot (Tokyo); 1994 Feb; 47(2):253-6. PubMed ID: 8150724
    [No Abstract]   [Full Text] [Related]  

  • 31. Absorption of ester prodrugs in Caco-2 and rat intestine models.
    He X; Sugawara M; Takekuma Y; Miyazaki K
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2604-9. PubMed ID: 15215116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.
    Harding SM; Williams PE; Ayrton J
    Antimicrob Agents Chemother; 1984 Jan; 25(1):78-82. PubMed ID: 6703686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activities of cefoperazone, cefotaxime, cefuroxime, and cephalothin against 128 clinical isolates.
    Garcia-Rodriguez JA
    Clin Ther; 1980; 3(Spec Issue):117-22. PubMed ID: 6248220
    [No Abstract]   [Full Text] [Related]  

  • 34. ["In vitro" activity of cefamandole, cefalotin, cefoxitin and cefuroxim against enterobacteria and Staphylococcus aureus isolated in hospital (author's transl)].
    Thabaut A; Durosoir JL; Saliou P
    Pathol Biol (Paris); 1979 Dec; 27(10):649-54. PubMed ID: 395496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Laboratory and clinical studies on cefuroxime (author's transl)].
    Nishimura T; Hiromatsu K; Takashima T; Tabuki K; Kotani Y
    Jpn J Antibiot; 1979 Dec; 32(12):1211-8. PubMed ID: 393845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat.
    Ruiz-Carretero P; Nacher A; Merino-Sanjuan M; Casabo VG
    Int J Pharm; 2000 Jul; 202(1-2):89-96. PubMed ID: 10915930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
    Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment.
    Brink HS; Huisman RM; Geerlings W; de Jong PE
    Adv Perit Dial; 1994; 10():179-82. PubMed ID: 7999822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
    Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of new oral carbapenems with 1-methyl-5-oxopyrrolidin-3-ylthio moiety.
    Kanno O; Miyauchi M; Shibayama T; Ohya S; Kawamoto I
    J Antibiot (Tokyo); 1999 Oct; 52(10):900-7. PubMed ID: 10604760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.